Pennant Group
PNTG
39.62
-0.34
-0.84%
Pennant Group
US · PNTG
#3029 by market cap
Listed 1970
39.62
-0.34
-0.84%
Live - 5344 symbols - heartbeat 372s ago
· 2026-10-07 19:54
After-hours
39.62
0.00%
- Market cap
- 1.38B
- P/E (TTM)i
- 43.54
- P/Bi
- 3.85
- EPSi
- 0.84
- Div yieldi
- 0.00%
- 52W posi
- 85%
Reader sentiment
Are you bullish or bearish on PNTG?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.70, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +36.31% YoY
Margins
- Gross margin
- 13.77%
- Operating margin
- 5.37%
- Net margin
- 3.12%
Key ratios & quality
- Enterprise valuei
- 1.57B
- PEG ratioi
- 0.67
- Altman Z-Scorei
- 2.70
PEG uses trailing P/E against the 3-year net income growth rate (64.51%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 286.06M | 338.53M | 390.95M | 439.69M | 473.24M | 544.89M | 695.24M | 947.71M |
| Gross profit | 42.44M | 44.62M | 54.89M | 48.60M | 58.59M | 67.04M | 93.76M | 130.50M |
| Selling & admin expenses | 18.84M | 35.14M | 31.30M | 36.26M | 33.98M | 36.67M | 50.21M | 71.08M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 20.63M | 5.67M | 18.92M | 7.55M | 19.70M | 25.24M | 37.43M | 50.89M |
| Pretax profit | 20.63M | 5.26M | 17.90M | 2.73M | 8.89M | 19.58M | 31.37M | 45.63M |
| Tax | 4.35M | 2.09M | 2.35M | 582.00K | 1.65M | 5.67M | 7.03M | 11.87M |
| Net profit | 16.28M | 3.18M | 15.55M | 2.15M | 7.24M | 13.91M | 24.34M | 33.76M |
| Basic EPS | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Diluted EPS | 0.56 | 0.11 | 0.52 | 0.09 | 0.22 | 0.44 | 0.70 | 0.84 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 209.84M | 219.50M | 229.04M | 289.32M | 285.36M | 297.98M |
| Gross profit | 29.38M | 30.30M | 31.55M | 39.27M | 39.60M | 41.92M |
| Selling & admin expenses | 14.84M | 17.60M | 19.30M | 19.34M | 19.69M | 21.61M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 12.65M | 10.48M | 10.19M | 17.57M | 17.30M | 17.20M |
| Pretax profit | 11.38M | 10.58M | 9.40M | 14.27M | 14.09M | 14.83M |
| Tax | 2.85M | 2.60M | 2.52M | 3.90M | 3.79M | 3.94M |
| Net profit | 8.52M | 7.98M | 6.89M | 10.38M | 10.29M | 10.90M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.22 | 0.20 | 0.17 | 0.24 | 0.24 | 0.25 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 29.12M | 38.68M | 59.60M | 75.84M | 73.82M | 80.08M | 122.86M | 167.41M |
| Cash & ST investments | 41.00K | 402.00K | 43.00K | 5.19M | 2.08M | 6.06M | 24.25M | 17.02M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 98.15M | 447.75M | 506.98M | 530.30M | 512.12M | 539.69M | 679.52M | 968.18M |
| Total current liabilities | 29.55M | 51.19M | 89.02M | 71.64M | 70.25M | 71.55M | 101.70M | 147.26M |
| Short-term debt | -- | 12.29M | 14.11M | 16.12M | 16.63M | 17.12M | 19.67M | 30.01M |
| Long-term debt | -- | 18.53M | 8.28M | 51.37M | 62.89M | 63.91M | -- | 168.84M |
| Total liabilities | 32,863,000.00 | 376,639,000.00 | 405,804,000.00 | 416,053,000.00 | 386,462,000.00 | 394,176,000.00 | 367,556,000.00 | 593,927,000.00 |
| Total equity | 65.29M | 71.11M | 101.17M | 114.24M | 125.66M | 145.52M | 311.97M | 374.25M |
| Retained earnings | 0 | -3.80M | 11.95M | 14.64M | 21.28M | 34.66M | 57.22M | 86.80M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 123.89M | 127.37M | 113.97M | 167.41M | 152.82M | 183.59M |
| Cash & ST investments | 5.22M | 14.39M | 2.34M | 17.02M | 4.91M | 15.27M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 743.62M | 751.42M | 753.64M | 968.18M | 956.48M | 1.04B |
| Total current liabilities | 87.97M | 104.94M | 109.35M | 147.26M | 128.58M | 152.41M |
| Short-term debt | 20.56M | 20.67M | 21.97M | 30.01M | 36.85M | 38.05M |
| Long-term debt | 52.50M | 37.00M | 26.00M | 168.84M | 164.67M | 192.50M |
| Total liabilities | 420,597,000.00 | 417,790,000.00 | 410,598,000.00 | 593,927,000.00 | 567,048,000.00 | 632,849,000.00 |
| Total equity | 323.03M | 333.63M | 343.04M | 374.25M | 389.44M | 404.44M |
| Retained earnings | 65.00M | 72.08M | 78.16M | 86.80M | 95.32M | 104.40M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 23.28M | 9.55M | 50.20M | -18.22M | 9.04M | 33.09M | 39.30M | 48.29M |
| Depreciation & amortization | 2.96M | 3.81M | 4.68M | 4.78M | 4.90M | 5.13M | 6.12M | 8.54M |
| Free cash flow | 19.67M | 2.84M | 42.95M | -24.53M | -5.13M | 24.99M | 30.31M | 36.26M |
| Dividends paid | 0 | -11.60M | 0 | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -394.00K | -65.00K | -- | 1.08M | 579.00K | 119.00M | 552.00K |
| Ending cash balance | 41.00K | 402.00K | 43.00K | 5.19M | 2.08M | 6.06M | 24.25M | 17.02M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -21.23M | 34.64M | 13.92M | 20.96M | -3.41M | 21.83M |
| Depreciation & amortization | 1.89M | 2.22M | 2.06M | 2.36M | 2.62M | 3.11M |
| Free cash flow | -23.19M | 31.58M | 10.47M | 17.40M | -8.68M | 15.49M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 5.22M | 14.39M | 2.34M | 17.02M | 4.91M | 15.27M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 28.30 | 4.01 | 18.78 | 2.61 | 5.75 | 10.24 | 10.40 | 9.45 |
| ROA %i | 16.82 | 0.93 | 3.30 | 0.52 | 1.27 | 2.54 | 3.70 | 3.59 |
| ROIC %i | 28.30 | 0.70 | 4.09 | 0.96 | 2.14 | 3.83 | 5.40 | 5.11 |
| 5-year avg ROE %i | -- | -- | -- | 14.33 | 11.89 | 8.28 | 9.55 | 7.69 |
| EBIT margin %i | 7.21 | 1.67 | 4.90 | 1.06 | 2.69 | 4.68 | 5.51 | 5.52 |
| FCF / sales %i | 6.88 | 0.84 | 10.99 | -- | -- | 4.59 | 4.36 | 3.83 |
| Current ratioi | 0.99 | 0.76 | 0.67 | 1.06 | 1.05 | 1.12 | 1.21 | 1.14 |
| Quick ratioi | 0.83 | 0.64 | 0.53 | 0.83 | 0.79 | 0.94 | 1.04 | 0.95 |
| Debt / assetsi | 0.00 | 74.79 | 62.92 | 66.99 | 63.77 | 61.08 | 40.19 | 46.81 |
| LT debt / equityi | -- | 453.61 | 315.69 | 307.74 | 256.12 | 222.68 | 86.41 | 127.22 |
| Interest coveragei | -- | 13.83 | 15.45 | 2.41 | 3.33 | 4.31 | 5.51 | 7.83 |
| Revenue CAGR (3Y) %i | -- | 15.94 | 15.92 | 15.41 | 11.81 | 11.70 | 16.50 | 26.05 |
| Net income CAGR (3Y) %i | -- | -31.41 | 16.85 | -44.40 | 37.67 | -5.28 | 103.02 | 64.51 |
| FCF CAGR (3Y) %i | -- | -39.67 | 44.90 | -- | -- | -16.52 | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 11.28 | 11.44 | 10.87 | 9.45 | 9.34 | 9.61 |
| ROA %i | 3.85 | 3.96 | 3.81 | 3.59 | 3.57 | 3.61 |
| ROIC %i | 5.38 | 5.54 | 5.08 | 5.11 | 5.10 | 5.42 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 5.65 | 5.57 | 5.20 | 5.52 | 5.56 | 5.74 |
| FCF / sales %i | 1.30 | 4.06 | 4.26 | 3.83 | 4.96 | 3.15 |
| Current ratioi | 1.41 | 1.21 | 1.04 | 1.14 | 1.19 | 1.20 |
| Quick ratioi | 1.14 | 1.05 | 0.90 | 0.95 | 0.99 | 0.97 |
| Debt / assetsi | 44.82 | 41.71 | 40.18 | 46.81 | 47.34 | 47.62 |
| LT debt / equityi | 103.01 | 93.45 | 87.24 | 127.22 | 120.21 | 126.91 |
| Interest coveragei | 6.64 | 7.48 | 10.81 | 7.83 | 6.66 | 5.92 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Home Health and Hospice Services is the largest reported line at 79.65% of revenue, across 3 reported segments.
- The next-largest line, Senior Living Services, is a distant second at 19.63% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Home Health and Hospice Services79.65%
Senior Living Services19.63%
All other0.72%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.